"10.1371_journal.pone.0105344","plos one","2014-08-28T00:00:00Z","Mathias Gehrmann; Stefan Stangl; Gemma A Foulds; Rupert Oellinger; Stephanie Breuninger; Roland Rad; Alan G Pockley; Gabriele Multhoff","Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom; Medical Department II, Translational Gastroenterological Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany; Clinical Cooperation Group (CCG) Innate Immunity in Tumor Biology, Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt, Munich, Germany","Conceived and designed the experiments: GM. Performed the experiments: MG GAF SB GM SS. Analyzed the data: MG GAF SB GM SS. Contributed reagents/materials/analysis tools: GM RR RO SS. Contributed to the writing of the manuscript: GM MG GAF AGP SS.","This study was partly funded by multimmune GmbH. The membrane Hsp70 phenotype on viable tumor and metastatic cells of patients was determined by flow cytometry using an FITC-conjugated cmHsp70.1 monoclonal antibody (mAb, multimmune GmbH, Germany). Gabriele Multhoff declares to have filed a patent relating to the TPP peptide pertinent to this article (Peptide-based compounds and their uses for tumor imaging and targeting). Gabriele Multhoff is a PLOS ONE Editorial Board member. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","08","Mathias Gehrmann","MG",8,TRUE,1,5,5,NA,TRUE,TRUE,FALSE,0,NA,FALSE
